The present application relates generally to medical treatment systems, and more particular, to a fluid pouch, system, and method for storing fluid from a tissue site.
Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but one particular application of reduced pressure involves treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at the wound site. Together these benefits result in increased development of granulation tissue and faster healing times. Typically, reduced pressure is applied by a reduced pressure source to tissue through a porous pad or other manifold device. In many instances, wound exudate and other liquids from the tissue site are collected within a canister to prevent the liquids from reaching the reduced pressure source.
The problems presented by existing reduced pressure systems are solved by the systems and methods of the illustrative embodiments described herein. In one embodiment, a system for storing fluid removed from a tissue site includes a reduced-pressure source operable to supply reduced pressure and a manifold adapted to distribute the reduced pressure. A drape is provided for covering the manifold, and the drape includes an aperture through which liquid from the tissue site is transferred. A flexible fluid pouch is provided in fluid communication with the aperture and is positioned adjacent the drape. The fluid pouch includes at least one baffle and a fluid channel at least partially defined by the at least one baffle. The fluid channel is operable to store liquid from the tissue site when the reduced pressure is applied through the fluid channel.
In another embodiment, an apparatus for storing liquid from a tissue site includes a drape having an aperture and a fluid pouch in fluid communication with the aperture. The fluid pouch includes at least one baffle and a fluid channel at least partially defined by the at least one baffle. The fluid channel is operable to store liquid from the tissue site when reduced pressure is applied through the fluid channel.
In still another embodiment, an apparatus for storing liquid from a tissue site is provided. The apparatus includes a drape having an aperture and an expandable fluid pouch coupled to the drape such that the fluid pouch is in fluid communication with the aperture. The fluid pouch is operable to transfer reduced pressure to the aperture such that the liquid from the tissue site is drawn into the fluid pouch. The fluid pouch includes a cavity that stores the liquid that is drawn from the tissue site.
In yet another embodiment, a method for storing liquid from a tissue site includes applying a drape and a fluid pouch to the tissue site, the drape having an aperture. The fluid pouch includes at least one baffle and a fluid channel at least partially defined by the at least one baffle. The fluid channel is operable to store liquid from the tissue site. The method further includes supplying a reduced pressure to the fluid pouch and storing the liquid in the fluid channel.
In another embodiment, a method of manufacturing an apparatus for storing liquid from a tissue site includes forming a flexible fluid pouch. The fluid pouch includes at least one baffle and a fluid channel at least partially defined by the at least one baffle. The fluid channel is operable to store liquid from the tissue site.
Other objects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
In the following detailed description of several illustrative embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown by way of illustration specific preferred embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the illustrative embodiments are defined only by the appended claims.
The term “reduced pressure” as used herein generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure reduction applied to the tissue site may be significantly less than the pressure reduction normally associated with a complete vacuum. Reduced pressure may initially generate fluid flow in the area of the tissue site. As the hydrostatic pressure around the tissue site approaches the desired reduced pressure, the flow may subside, and the reduced pressure is then maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.
The term “tissue site” as used herein refers to a wound or defect located on or within any tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. The term “tissue site” may further refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it is desired to add or promote the growth of additional tissue. For example, reduced pressure tissue treatment may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
Referring to
The conduit 118 may include one or more paths or lumens through which fluid may flow. For example, the conduit 118 may include two or more lumens, one of which may be used to deliver reduced pressure to the tissue site and one of which may be used to determine the level of reduced pressure at the tissue site 105. Alternatively, one of the lumens may be used to deliver fluids, such as air, antibacterial agents, antiviral agents, cell-growth promotion agents, irrigation fluids, or other chemically active agents, to the tissue site 105. If fluid delivery is provided by one of the lumens, that particular lumen will likely be configured to bypass the fluid pouch 130.
The conduit 118 may fluidly communicate with the reduced pressure dressing 115 through a tubing adapter 145. The tubing adapter 145 permits the passage of fluid, such as air, from the manifold 120 to the conduit 118, and vice versa. In another embodiment, the reduced-pressure treatment system 100 does not include the tubing adaptor 145. In this embodiment, the conduit 118 may be inserted directly into a component of the dressing 115. The tubing adaptor 145 may be located anywhere relative to the dressing 115. For example, although
In the embodiment illustrated in
The reduced-pressure treatment system 100 may include a reduced pressure feedback system 155 operably associated with the other components of the reduced-pressure treatment system 100 to provide information to a user of the reduced-pressure treatment system 100 indicating a relative or absolute amount of pressure that is being delivered to the tissue site 105 or that is being generated by the reduced-pressure source 110. Examples of feedback systems include, without limitation, pop valves that activate when the reduced pressure rises above a selected value and deflection pop valves.
The reduced-pressure treatment system 100 may include a volume detection system 157 to detect the amount of fluid present in the fluid pouch 130, a blood detection system 159 to detect the presence of blood in exudate drawn from the tissue site 105 (including the exudate that is present in the fluid pouch 130), a temperature monitoring system 162 to monitor the temperature of the tissue site 105, an infection detection system 165 to detect the presence of infection at the tissue site 105, and/or a flow rate monitoring system 167 to monitor the flow rate of fluids drawn from tissue site 105. The infection detection system 165 may include a foam or other substance that changes color in the presence of bacteria. The foam or other substance may be operably associated with the dressing 115 or the conduit 118 such that the color changing material is exposed to exudate from the tissue site 105. In addition to the above-mentioned components and systems, the reduced-pressure treatment system 100 may include valves, regulators, switches, and other electrical, mechanical, and fluid components to facilitate administration of reduced-pressure treatment to the tissue site 105.
The distribution manifold 120 is adapted to be positioned at the tissue site 105, and the cover 125, or drape, is positioned over the distribution manifold 120 to maintain reduced pressure beneath the cover 125 at the tissue site 105. The distribution manifold 120 of the reduced pressure dressing 115 is adapted to contact the tissue site 105. The distribution manifold 120 may be partially or fully in contact with the tissue site 105 being treated by the reduced pressure dressing 115. When the tissue site 105 is a wound, the distribution manifold 120 may partially or fully fill the wound.
The distribution manifold 120 may be any size, shape, or thickness depending on a variety of factors, such as the type of treatment being implemented or the nature and size of the tissue site 105. For example, the size and shape of the distribution manifold 120 may be customized by a user to cover a particular portion of the tissue site 105, or to fill or partially fill the tissue site 105. The distribution manifold 120 may have, for example, a square shape, or may be shaped as a circle, oval, polygon, an irregular shape, or any other shape.
In one illustrative embodiment, the distribution manifold 120 is a foam material that distributes reduced pressure to the tissue site 105 when the distribution manifold 120 is in contact with or near the tissue site 105. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, the distribution manifold 120 is an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. If an open-cell foam is used, the porosity may vary, but is preferably about 400 to 600 microns. The flow channels allow fluid communication throughout the portion of the manifold 120 having open cells. The cells and flow channels may be uniform in shape and size, or may include patterned or random variations in shape and size. Variations in shape and size of the cells of manifold result in variations in the flow channels, and such characteristics may be used to alter the flow characteristics of fluid through the manifold 120.
In the example in which the distribution manifold 120 is made from a hydrophilic material, the distribution manifold 120 also functions to wick fluid away from the tissue site 105, while continuing to provide reduced pressure to the tissue site 105 as a manifold. The wicking properties of the distribution manifold 120 draw fluid away from the tissue site 105 by capillary flow or other wicking mechanisms. An example of a hydrophilic foam is a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
The distribution manifold 120 may further promote granulation at the tissue site 105 when a reduced pressure is applied through the reduced pressure dressing 115. For example, any or all of the surfaces of the distribution manifold 120 may have an uneven, coarse, or jagged profile that causes microstrains and stresses at the tissue site 105 when reduced pressure is applied through the distribution manifold 120. These microstrains and stresses have been shown to increase new tissue growth.
In one embodiment, the distribution manifold 120 may be constructed from bioresorbable materials that do not have to be removed from a patient's body following use of the reduced pressure dressing 115. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The distribution manifold 120 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the distribution manifold 120 to promote cell-growth. A scaffold is a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
Referring still to
In the embodiment illustrated in
In one embodiment, the cover 125 is configured to provide a sealed connection with the tissue surrounding the manifold 120 and the tissue site 105. The sealed connection may be provided by an adhesive layer positioned along a perimeter of the cover 125, or on any portion of the cover 125, to secure the cover 125 to the manifold 120 or the tissue surrounding the tissue site 105. The adhesive may be pre-positioned on the cover 125 or may be sprayed or otherwise applied to the cover 125 immediately prior to installing the cover 125. Prior to the application of the cover 125 to the tissue site 105, the adhesive may also be covered by an adhesive support layer or removable backing. The adhesive support layer may provide rigidity to the drape prior to application and may also aid in the actual application of the cover 125 onto the tissue site 105. The adhesive support layer may be peeled off or otherwise removed before applying the cover 125 to the tissue site 105.
In one embodiment, the cover 125 has an aperture 127. Liquid, such as exudate, from the tissue site 105 may pass through the cover 125 via the aperture 127. In some instances, the liquid may also contain solid particles. Although the aperture 127 is shown to have a circular cross-sectional shape in
The dressing 115 also includes the fluid pouch 130, which may be used to store liquid, such as exudate, from the tissue site 105. The fluid pouch 130 may be coupled to the cover 125 such that the fluid pouch 130 is in fluid communication with the aperture 127. In one embodiment, liquid from the tissue site 105 may pass through the aperture 127 and into the fluid pouch 130 as a result of reduced pressure being applied to the dressing 115. A one-way valve may be located at or near the inlet to the fluid pouch 130 so that fluid in the fluid pouch 130 is restrained from entering the aperture 127. As used herein, the term “coupled” includes coupling via a separate object, and also includes direct coupling. In the case of direct coupling, the two coupled objects touch each other in some way. The term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term “coupled” includes chemical coupling, such as via a chemical bond. The term “coupled” may also include mechanical, thermal, or electrical coupling. The term “coupled” may also include fluidly coupled, in which case a first object that is coupled to a second object is in fluid communication with that second object.
In another embodiment, the fluid pouch 130 may be positioned adjacent or in contact with the cover 125. The term “adjacent” as used herein refers to the positional relationship of two or more objects. Two objects that are adjacent includes two objects that are close to one another and that may, but do not necessarily have to, contact one another. An object that is adjacent to another object may be immediately adjacent with no intervening structure between the two objects, or alternatively, may include two objects that have intervening structures or objects between the two objects.
The fluid pouch 130 may include baffles, which help define fluid channels, for directing fluid flow as will be described further below. Numerous illustrative embodiments of the fluid pouch 130 are possible and a number of illustrative embodiments follow.
In an embodiment, such as that illustrated in
In one embodiment, either or both of the first sheet 132 and the second sheet 133 is transparent. The transparency of either or both of the first sheet 132 and the second sheet 133 exposes the amount of liquid from the tissue site 105 that is stored in the fluid pouch 130. Thus, a person is made aware of the remaining liquid capacity of the fluid pouch 130 and the possible need to replace or empty the fluid pouch 130.
In another embodiment, the fluid pouch 130 is an expandable fluid pouch that expands as liquid from the tissue site 105 fills the fluid pouch 130. In one non-limiting example, the fluid pouch 130 may expand in either or both of the directions indicated by bi-directional arrow 149 as liquid from the tissue site 105 fills the fluid pouch 130. However, the fluid pouch 130 may expand in other directions as well. The edges of the fluid pouch 130 may also have a pleated construction to facilitate the expansion of the fluid pouch 130.
The fluid pouch 130 may be made from any material, such as a flexible, stretchable, expandable, and/or rigid material. Non-limiting examples of the materials from which the fluid pouch 130 may be made include polymer films of various thicknesses including polyurethane, polypropylene, PVC, polyethylene, and/or polyamides, as well as coated fabrics or laminations of any one or combination of the above.
In one embodiment, a method for storing liquid from the tissue site 105 may include applying the manifold 120 to the tissue site 105 and at least partially covering the manifold 120 with the cover 125. In another embodiment, the cover 125 may be applied directly to the tissue site 105 without the manifold 120. In another embodiment, the method may include applying the cover 125 and a fluid pouch to the tissue site; in this embodiment, either or both of the cover 125 and the fluid pouch may or may not directly touch the tissue site. In another embodiment, the method may also include coupling a fluid pouch as in any of the illustrative embodiment disclosed herein to the cover 125 such that the fluid pouch is in fluid communication with the aperture 127. The method may also include supplying a reduced pressure from the reduced-pressure source 110. The reduced pressure may be supplied to the tissue site 105, the manifold 120, and/or the fluid pouch 130. The reduced pressure may also cause liquid, such as exudate, from the tissue site 105 to enter the fluid pouch 130. The liquid may be stored in the fluid pouch 130.
In another embodiment, a method of manufacturing an apparatus for storing liquid from the tissue site 105 may include forming a fluid pouch as in any of the illustrative embodiments disclosed herein, including the fluid pouch 130. In another embodiment, the method may also include providing the cover 125 and coupling the fluid pouch 130 to the cover 125 such that the fluid pouch 130 is in fluid communication with the aperture 127. In another embodiment, the method may also include providing the manifold 120, and covering at least a portion of the manifold 120 with the cover 125.
Referring to
All of the baffles 370 are substantially parallel to one another to form a plurality of fluid channel portions 390-396 of fluid channel 375. Each of the fluid channel portions 390-396 are in fluid communication with an adjacent fluid channel portion. Such fluid communication is facilitated by gaps 382 between the baffles 370 and a wall of the fluid pouch 330.
The fluid pouch 330 may include any number of baffles and any number of fluid channel portions. For example, the number of baffles and fluid channel portions may be varied to increase or decrease the liquid storage capacity of the fluid pouch 330. The length of the fluid channel 375 or the fluid channel portions 390-396 may also be increased or decreased to vary the liquid storage capacity of the fluid pouch 330.
All of the fluid channel portions 390-396 may be substantially parallel to one another to form a plurality of rows. The fluid pouch 330 includes such a row-like structure. At least two of the fluid channel portions 390-396 are at least partially defined by a same baffle, including any one of baffles 370. For example, both of fluid channel portions 390 and 391 are partially defined by the same baffle because one side of the shared baffle defines a wall of the fluid channel portion 390 and an opposite side of the shared baffle defines a wall of the fluid channel portion 391. Similarly, each of fluid channel portions 393 and 394 are partially defined by the same baffle because one side of the shared baffle defines a wall of the fluid channel portion 393 and an opposite side of the shared baffle defines a wall of the fluid channel portion 394.
For any two fluid channel portions that share a same baffle, a direction of fluid flow in a first of the fluid channel portions may be in an opposite direction than a direction of fluid flow for a second of the fluid channel portions. For example, fluid channel portions 390 and 391, which are partially defined by a same baffle, have fluid flow directions that are opposite from one another, as indicated by arrows 378. Similarly, fluid channel portions 393 and 394, which are partially defined by a same baffle, have fluid flow directions that are opposite from one another, as indicated by arrows 378.
The fluid pouch 330 also includes an inlet 398 and an outlet 399. Liquid from the tissue site 105 enters the fluid channel 375 via the inlet 398. In one embodiment, a reduced-pressure source causes a gas, such as air, to enter the inlet 398, pass through the fluid channel 375, and exit the outlet 399 to cause a reduced pressure to be transferred though the fluid channel 375 and applied to a tissue site. As a result of this reduced pressure, liquid from the tissue site may pass through an aperture in a drape and enter the fluid pouch 330 via the inlet 398. The inlet 398 may also include a one-way valve that allows gas and/or liquid to enter the fluid pouch 330, but does not allow gas and/or liquid to exit the fluid pouch 330 via the inlet 398. In addition, the outlet 399 may include a one-way valve that allows gas to exit the fluid pouch 300, but does not allow gas to enter the fluid pouch 330 via the outlet 399. The outlet 399 may include a liquid-air separator, such as a hydrophobic filter or oleophobic filter, to prevent liquids from exiting the fluid pouch 330.
In one embodiment, the fluid pouch 330 may also include a tube that fluidly couples the aperture (e.g., aperture 127 in
The fluid channel 375 may also store liquid from the tissue site, including any liquid that enters the fluid channel 375 via the inlet 398. In one embodiment, the fluid pouch 330 includes an absorbent material 372 in the fluid channel 375. The absorbent material 372 stores, or immobilizes, the liquid from a tissue site.
The absorbent material 372 may be any substance capable of storing a liquid, such as exudate. For example, the absorbent material 372 may form a chemical bond with exudate from the tissue site. Non-limiting examples of the absorbent material 372 include super absorbent fiber/particulates, hydrofibre, sodium carboxymethyl cellulose, and/or alginates. In addition, the fluid channel 375 may include any amount of absorbent material 372. For example, the amount of absorbent material 372 may be varied to increase or decrease the liquid storage capacity of the fluid pouch 330. The presence of the absorbent material 372 may also help to minimize fluid loss or reflux.
Referring to
Reduced pressure that is introduced into the fluid channel 375 via the outlet 399 causes the liquid 412 to enter the fluid channel 375 via the inlet 398. The liquid 412 at least partially occupies fluid channel portions 390-393, while fluid channel portions 394-396 contain little or none of the liquid 412.
In another embodiment, the absorbent material 372 may occlude the fluid channel 375 when all of the absorbent material 372 in the fluid channel 375 is saturated with the liquid 412. Occluding the fluid channel 375 in this manner prevents reduced pressure from being transferred through the fluid pouch 330, and may possibly prevent spillage or overflow of the liquid 412 from the fluid pouch 330.
In another embodiment, the fluid pouch 330 may have multiple fluid channels that may or may not be in fluid communication with one another. In addition, the fluid pouch 330 may have more than one inlet and/or outlet. In the embodiment in which the fluid pouch 330 has more than one fluid channel, each of the fluid channels may have a respective inlet and/or outlet.
Referring to
A baffle 572 of fluid pouch 530 is a spiraling baffle that emanates from a central portion of the fluid pouch 530. In addition, a fluid channel 575 emanates from a central inlet 598 to form a spiraling fluid channel that is at least partially defined by the spiraling baffle 572. The central inlet 598 is functionally analogous to the inlet 398 in
Although no absorbent material, such as absorbent material 372, is shown in the fluid pouch 530, the fluid channel 575 may include an absorbent material as described in any of the illustrative embodiments herein. Also, the number of revolutions of the fluid channel 575 around the central inlet 598 may be varied to increase or decrease the liquid storage capacity of the fluid pouch 530.
Outlet 599 is functionally analogous to the outlet 399 in
Referring to
The fluid channel portions 392 and 393 are formed by coupling portions of sheet 633 to sheet 632. The sheet 632 is substantially flat and the sheet 633 includes curved portions over the fluid channel portions 392 and 393. In one embodiment, the absorbent material 372 covers at least a portion of the sheet 632. The sheet 633 may be uncovered by the absorbent material 372. In addition, an inner portion of the sheet 633 is adhered to an inner portion of the sheet 632 to form the baffle 370. An inner portion of the sheet 633 may be adhered to an inner portion of the sheet 632 in a variety of ways. For example, an inner portion of the sheet 633 may be welded, glued, sewed, pinned, snapped, or otherwise bonded onto an inner portion of the sheet 632. In the example in which an inner portion of the sheet 633 is welded onto an inner portion of the sheet 632, the welding may be achieved using heat, ultrasonics, radio frequencies, a solvent, and/or other welding methods.
In one embodiment, the fluid channel portion 392 includes a passageway 618 through which reduced pressure is transferable when the absorbent material 615 is saturated with liquid from the tissue site. In this embodiment, the passageway 618 is present in the fluid channel portion 392 when the absorbent material 615 is partially or fully saturated with liquid. By maintaining the passageway 618 when the absorbent material 615 is saturated with liquid, reduced pressure from a reduced-pressure source may continue to be transferred to a tissue site via the fluid pouch.
Referring to
Referring to
Referring to
In one embodiment, no absorbent material is contained in the cavity 980. In another embodiment, the cavity 980 includes absorbent material 982. The absorbent material 982 is analogous to the absorbent material 372 in
The fluid pouch 930 may be formed with an envelope 984 that at least partially encloses the cavity 980. In one embodiment, the envelope 984 fully encloses the cavity 980. The envelope 984 may be composed of any of a variety of materials. In one embodiment, the envelope 984 may be composed of a same or similar material as fluid pouch 130 in
In one embodiment, the envelope 984 may be a manifolding envelope that may be composed of a material that is operable to distribute and/or transfer a liquid, including exudate from a tissue site. For example, the envelope 984 may be composed of an open-cell foam. In this example, the open-cell foam may be reticulated or non-reticulated, and may be hydrophobic or hydrophilic. In another example, the envelope 984 may be made from a non-woven material, including a non-woven material manufactured by Libeltex, Dupont, Freudenberg, or Ahlstrom. In another example, the envelope 984 may be composed of a three dimensional material, including Supracor® fusion bonded honeycomb or XD spacer fabric manufactured by Baltex. In another example, the envelope 984 may be composed of a molded matrix.
The envelope 984 may be composed of layers 986 and 988. In the embodiment in which the envelope 984 is a manifolding envelope, the layers 986 and 988 may be manifolding layers. A perimeter of the layer 986 may be bonded to a perimeter of the layer 988 at bonding sites 990 and 991. Any bonding method may be used, including those previously mentioned for welding.
Turning now to
In addition, the manifolding envelope 1084 distributes liquid 1092 along a perimeter of the cavity 980 in a direction indicated by arrows 1060. Without the manifolding envelope 1084, in some circumstances the absorbent material 982 may swell in the immediate area of liquid entry into the cavity 980, and possibly cause a restriction in flow before much of the absorbent material 982 is used. The manifolding envelope 1084 helps to ensure that a greater portion of the absorbent material 982 is exposed to the liquid 1092, thereby facilitating larger and more efficient liquid storage.
Referring to
The reduced-pressure treatment system 1100 includes a connection tube 1112. The cover 125 is coupled to the fluid pouch 1130 via the connection tube 1112 such that the connection tube 1112 facilitates fluid communication between the aperture 127 and the fluid pouch 1130. One end of the connection tube 1112 is fluidly coupled to the aperture 127, and another end of the connection tube 1112 is fluidly coupled to an inlet of a fluid pouch 1130. In one embodiment, the connection tube 1112 allows the fluid pouch 1130 to be remotely located from the manifold 120 and/or the cover 125. Fluid may exit the fluid pouch 1130 via an outlet connector 1135, which is functionally analogous to the tubing adaptor 145 in
In one example, the fluid pouch 1130 may be located on a patient's skin at a site that is adjacent or remote from the manifold 120 and/or the cover 125. In this example, the fluid pouch 1130 may be adhered to the patient's skin and/or clothing using adhesive layer 1142 and/or a mechanical connection (e.g., strap). In another example, the fluid pouch 1120 may be connected to or mated with any object that is remote from the manifold 120 and/or the cover 125. For example, the fluid pouch may mate with a hospital bed, wheel chair, and/or walking boot. The fluid pouch 1130 may be adhered to an object or person using any means of adherence.
It should be apparent from the foregoing that an invention having significant advantages has been provided. While the invention is shown in only a few of its forms, it is not just limited but is susceptible to various changes and modifications without departing from the spirit thereof.
This application is a continuation U.S. patent application Ser. No. 14/229,457, filed Mar. 28, 2014, which is a continuation of U.S. patent application Ser. No. 12/617,792, filed Nov. 13, 2009, which claims the benefit of U.S. Provisional Application No. 61/114,827, filed Nov. 14, 2008, each of which is hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3367332 | Groves | Feb 1968 | A |
3376868 | Mondiadis | Apr 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3742952 | Magers et al. | Jul 1973 | A |
3774611 | Tussey et al. | Nov 1973 | A |
3779243 | Tussey et al. | Dec 1973 | A |
3826254 | Mellor | Jul 1974 | A |
3867939 | Moore et al. | Feb 1975 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4141361 | Snyder | Feb 1979 | A |
4149541 | Gammons et al. | Apr 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Adair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4529402 | Weilbacher et al. | Jul 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664652 | Weilbacher | May 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
D298279 | Lee et al. | Oct 1988 | S |
4787888 | Fox | Nov 1988 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4962761 | Golden | Oct 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4981474 | Bopp et al. | Jan 1991 | A |
4985019 | Michelson | Jan 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5112323 | Winkler et al. | May 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5176667 | DeBring | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5215539 | Schoolman | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342329 | Croquevielle | Aug 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5387207 | Dyer et al. | Feb 1995 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5549707 | Weaver | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5630855 | Lundback | May 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5710233 | Meckel et al. | Jan 1998 | A |
5941863 | Guidotti et al. | Aug 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6174306 | Fleischmann | Jan 2001 | B1 |
6241747 | Ruff | Jun 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6420622 | Johnston et al. | Jul 2002 | B1 |
6458109 | Henley et al. | Oct 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6626891 | Ohmstede | Sep 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
6979324 | Bybordi et al. | Dec 2005 | B2 |
7070584 | Johnson et al. | Jul 2006 | B2 |
7108683 | Zamierowski | Sep 2006 | B2 |
7276051 | Henley et al. | Oct 2007 | B1 |
7381859 | Hunt et al. | Jun 2008 | B2 |
7520872 | Biggie et al. | Apr 2009 | B2 |
7569742 | Haggstrom et al. | Aug 2009 | B2 |
7794438 | Henley et al. | Sep 2010 | B2 |
7846141 | Weston | Dec 2010 | B2 |
7863495 | Aali | Jan 2011 | B2 |
8062273 | Weston | Nov 2011 | B2 |
8216198 | Heagle et al. | Jul 2012 | B2 |
8251979 | Malhi | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8398614 | Blott et al. | Mar 2013 | B2 |
8449509 | Weston | May 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8551060 | Schuessler et al. | Oct 2013 | B2 |
8568386 | Malhi | Oct 2013 | B2 |
8679081 | Heagle et al. | Mar 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8926592 | Blott et al. | Jan 2015 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9198801 | Weston | Dec 2015 | B2 |
9211365 | Weston | Dec 2015 | B2 |
9289542 | Blott et al. | Mar 2016 | B2 |
20020016346 | Brandt et al. | Feb 2002 | A1 |
20020065494 | Lockwood et al. | May 2002 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020128578 | Johnston et al. | Sep 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020150720 | Howard et al. | Oct 2002 | A1 |
20020183702 | Henley et al. | Dec 2002 | A1 |
20020198504 | Risk et al. | Dec 2002 | A1 |
20040030304 | Hunt | Feb 2004 | A1 |
20040064132 | Boehringer et al. | Apr 2004 | A1 |
20040076662 | Riesinger | Apr 2004 | A1 |
20040186239 | Qin et al. | Sep 2004 | A1 |
20050070858 | Lockwood et al. | Mar 2005 | A1 |
20050137539 | Biggie et al. | Jun 2005 | A1 |
20050256437 | Silcock et al. | Nov 2005 | A1 |
20050261642 | Weston | Nov 2005 | A1 |
20050261643 | Bybordi et al. | Nov 2005 | A1 |
20060271020 | Huang et al. | Nov 2006 | A1 |
20070027414 | Hoffman et al. | Feb 2007 | A1 |
20070055209 | Patel et al. | Mar 2007 | A1 |
20070078366 | Haggstrom et al. | Apr 2007 | A1 |
20070185426 | Ambrosio et al. | Aug 2007 | A1 |
20070225663 | Watt et al. | Sep 2007 | A1 |
20070265585 | Joshi et al. | Nov 2007 | A1 |
20080082059 | Fink et al. | Apr 2008 | A1 |
20080119802 | Riesinger | May 2008 | A1 |
20080195017 | Robinson | Aug 2008 | A1 |
20080243044 | Hunt et al. | Oct 2008 | A1 |
20090082740 | Lockwood et al. | Mar 2009 | A1 |
20090227969 | Jaeb | Sep 2009 | A1 |
20090264807 | Haggstrom et al. | Oct 2009 | A1 |
20090326488 | Budig et al. | Dec 2009 | A1 |
20100069886 | Wilkes | Mar 2010 | A1 |
20100106106 | Heaton | Apr 2010 | A1 |
20100137775 | Hu et al. | Jun 2010 | A1 |
20110077571 | Andresen | Mar 2011 | A1 |
20140163491 | Schuessler et al. | Jun 2014 | A1 |
20150080788 | Blott et al. | Mar 2015 | A1 |
20160067107 | Cotton | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
550575 | Mar 1986 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
29 504 378 | Sep 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Jul 2000 | EP |
1905465 | Apr 2008 | EP |
692578 | Jun 1953 | GB |
2 195 255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 329 127 | Mar 1999 | GB |
2 333 965 | Aug 1999 | GB |
H08502194 | Mar 1996 | JP |
2001252349 | Sep 2001 | JP |
2008080137 | Apr 2008 | JP |
4129536 | Aug 2008 | JP |
71559 | Apr 2002 | SG |
8002182 | Oct 1980 | WO |
8704626 | Aug 1987 | WO |
90010424 | Sep 1990 | WO |
93009727 | May 1993 | WO |
1994008636 | Apr 1994 | WO |
94020041 | Sep 1994 | WO |
9605873 | Feb 1996 | WO |
9718007 | May 1997 | WO |
9913793 | Mar 1999 | WO |
0185248 | Nov 2001 | WO |
03045492 | Jun 2003 | WO |
2005105176 | Nov 2005 | WO |
2007133618 | Nov 2007 | WO |
2008013896 | Jan 2008 | WO |
2008036131 | Mar 2008 | WO |
2008041926 | Apr 2008 | WO |
2008100440 | Aug 2008 | WO |
2008104609 | Sep 2008 | WO |
2009066105 | May 2009 | WO |
2009066106 | May 2009 | WO |
2009068667 | Jun 2009 | WO |
Entry |
---|
NPD 1000 Negative Pressure Wound Therapy System, Kalypto Medical, pp. 1-4. |
Partial International Search Report dated Jul. 31, 2009 for PCT International Application No. PCT/US2009/036217. |
International Search Report and Written Opinion dated Oct. 19, 2009; PCT International Application No. PCT/US2009/036217. |
International Search Report and Written Opinion dated Jan. 5, 2010; PCT International Application No. PCT/US2009/057130. |
Partial International Search Report dated Jul. 31, 2009; PCT International Application No. PCT/US2009/036222. |
International Search Report and Written Opinion dated Dec. 15, 2009; PCT International Application No. PCT/US2009/036222. |
International Search Report and Written Opinion dated Feb. 24, 2010; PCT International Application No. PCT/US2009/057182. |
International Search Report and Written Opinion dated May 31, 2010 for PCT Application No. PCT/US2009/064364. |
Restriction Requirement dated Jun. 13, 2011 for U.S. Appl. No. 12/398,891. |
Response filed Jun. 24, 2011 for U.S. Appl. No. 12/398,891. |
Non-Final Office Action dated Jul. 21, 2011 for U.S. Appl. No. 12/398,891. |
Non-Final Office Action dated Jul. 20, 2011 for U.S. Appl. No. 12/398,904. |
Response filed Oct. 21, 2011 for U.S. Appl. No. 12/398,891. |
Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,891. |
Response filed Oct. 20, 2011 for U.S. Appl. No. 12/398,904. |
Interview Summary dated Oct. 27, 2011 for U.S. Appl. No. 12/398,904. |
European Extended Search Report for Application No. 09826823.8 dated Mar. 4, 2013. |
Examination Report for corresponding European Application No. 15152663.9, dated Jul. 31, 2017. |
Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery. |
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 198, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of be Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, Vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
Dattilo, Philip P., JR., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu.A., et al; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu.A., et al; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (certified translation). |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {hacek over (Z)}ivadinovi?, V. ?uki?, {hacek over (Z)}. Maksimovi?, ?. Radak, and P. Pe{hacek over (s)}ka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (copy and certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (copy and certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96, 167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C.® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
Number | Date | Country | |
---|---|---|---|
20170312407 A1 | Nov 2017 | US |
Number | Date | Country | |
---|---|---|---|
61114827 | Nov 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14229457 | Mar 2014 | US |
Child | 15648143 | US | |
Parent | 12617792 | Nov 2009 | US |
Child | 14229457 | US |